Artificial Pancreas Device System Market Expansion 2024-2033: Growth Drivers and Dynamics

The artificial pancreas device system global market report 2024 from The Business Research Company provides comprehensive market statistics, including global market size, regional shares, competitor market share, detailed segments, trends, and opportunities. This report offers an in-depth analysis of current and future industry scenarios, delivering a complete perspective for thriving in the industrial automation software market.

Artificial Pancreas Device System Market, 2024 report by The Business Research Company offers comprehensive insights into the current state of the market and highlights future growth opportunities.

Market Size –

The artificial pancreas device system market size has grown rapidly in recent years. It will grow from $1.59 billion in 2023 to $1.81 billion in 2024 at a compound annual growth rate (CAGR) of 13.9%. The growth in the historic period can be attributed to rising inflow of investment, growing government initiative in clinical research, growing demand for automated systems in glycemic control, intensive R&D efforts by industry players, and increasing geriatric population.

The artificial pancreas device system market size is expected to see rapid growth in the next few years. It will grow to $3.06 billion in 2028 at a compound annual growth rate (CAGR) of 14%. The growth in the forecast period can be attributed to growing prevalence of diabetes, increasing prevalence of pancreatic cancer, growing occurrence of diabetes and obesity, rising demand minimally invasive (MI) drug delivery systems, and driving innovation in diabetes management technology. Major trends in the forecast period include technological innovations, increasing research and development activities, increasing product approvals, partnerships and collaborations, and increasing activities in tele consultancy for follow-up.

Order your report now for swift delivery @
https://www.thebusinessresearchcompany.com/report/artificial-pancreas-device-system-global-market-report

Scope Of Artificial Pancreas Device System Market
The Business Research Company’s reports encompass a wide range of information, including:

1. Market Size (Historic and Forecast): Analysis of the market’s historical performance and projections for future growth.

2. Drivers: Examination of the key factors propelling market growth.

3. Trends: Identification of emerging trends and patterns shaping the market landscape.

4. Key Segments: Breakdown of the market into its primary segments and their respective performance.

5. Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.

6. Macro Economic Factors: Assessment of broader economic elements impacting the market.

Artificial Pancreas Device System Market Overview

Market Drivers –

The increasing prevalence of pancreatic cancer is expected to propel the growth of the artificial pancreas device system market going forward. Pancreatic cancer is a malignant tumor that originates in the pancreas, a gland located behind the stomach. Pancreatic cancer is influenced by a combination of lifestyle, genetic, medical, and environmental factors, along with genetic mutations causing hereditary pancreatitis, which can lead to chronic inflammation of the pancreas. An artificial pancreas device system (APDS) is primarily designed to help individuals with diabetes manage their blood sugar levels by automatically monitoring glucose and delivering the appropriate amount of insulin. For instance, in March 2024, Cancer Australia, a government agency, estimated that 4,506 new cases of pancreatic cancer were diagnosed in 2023, an increase from the 3,751 cases reported over the past five years. Therefore, the increasing prevalence of pancreatic cancer is driving the growth of the artificial pancreas device system market.

Market Trends –

Major companies operating in the artificial pancreas device system market are developing automated insulin delivery systems to enhance diabetes management by automatically monitoring blood glucose levels and delivering the appropriate amount of insulin. Automated insulin delivery systems aim to replicate the function of a healthy pancreas, reducing the burden of constant blood sugar monitoring and manual insulin administration for individuals with diabetes. For instance, in May 2023, Beta Bionics, a US-based medical equipment manufacturing company, received FDA 510(k) clearance for iLet Insulin-Only Bionic Pancreas System, an automated insulin delivery device. It is an artificial pancreas system designed to autonomously determine and deliver insulin doses to control blood glucose levels. A closed-loop system automatically adjusts insulin delivery based on the user’s glucose levels measured by a connected continuous glucose monitor (CGM). It only requires the user’s body weight and a meal size estimate to adjust insulin delivery automatically.

The artificial pancreas device system market covered in this report is segmented –

1) By Device Type: Threshold Suspend Device Systems, Control-To-Range Systems, Control-To-Target Systems
2) By Treatment Type: Bi-Hormonal, Insulin Only, Hybrid
3) By End-User: Hospitals, Medical Centers, Other End-Users

Get an inside scoop of the artificial pancreas device system market, Request now for Sample Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=18229&type=smp

Regional Insights –

North America was the largest region in the artificial pancreas device system market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the artificial pancreas device system market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Key Companies –

Major companies operating in the artificial pancreas device system market are Johnson & Johnson, Abbott Laboratories, Medtronic plc, DexCom Inc., Insulet Corporation, Tandem Diabetes Care Inc., Juvenile Diabetes Research Foundation (JDRF), Beta Bionics Inc., Glooko Inc., Bigfoot Biomedical Inc., CeQur SA, Medtrum Technologies Inc., Diabeloop SA, Beta-O2 Technologies Ltd, Pancreum Inc., TypeZero Technologies LLC, Inreda Diabetic B.V., Defymed SAS, Admetsys Corporation, DreaMed Diabetes Ltd

Table of Contents
1. Executive Summary
2. Artificial Pancreas Device System Market characterstics
3. Artificial Pancreas Device System Market Trends And Strategies
4. Artificial Pancreas Device System Market – Macro Economic Scenario
5. Global Artificial Pancreas Device System Market Size And Growth
…..

32. Global Artificial Pancreas Device System Market Competitive Benchmarking
33. Global Artificial Pancreas Device System Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Artificial Pancreas Device System Market
35. Artificial Pancreas Device System Market Future Outlook and Potential Analysis
36. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model